Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A rapid onset and short duration insulin secretogogue, mitiglinide, in combination with metformin versus metformin alone in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial for 6 months.

Next Previous
X
Search
Trial Profile

A rapid onset and short duration insulin secretogogue, mitiglinide, in combination with metformin versus metformin alone in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial for 6 months.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitiglinide/metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Elixir Pharmaceuticals

    • Most Recent Events

    • 16 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met, as reported in an Elixir Pharmaceuticals media release.
    • 20 Nov 2008 According to an Elixir pharmaceuticals media release, the results from this trial will support the submission of a new drug application to the U.S. FDA in 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top